Can the RSV vaccine protect the most vulnerable? new study aims to find out
NCT ID NCT07296120
First seen Jan 08, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This study tests whether the RSV vaccine Abrysvo can help blood cancer patients who have had a stem cell transplant or CAR-T therapy build immunity against RSV. Researchers will measure antibody levels before and after vaccination in 30 adults. The goal is to see if the vaccine triggers a strong enough immune response to prevent serious respiratory infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cooper University Hospital
Camden, New Jersey, 08103, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF, brand name Abrysvo)
What this could lead to
If it works, this could show that the RSV vaccine protects vulnerable blood cancer patients from severe respiratory infections after transplant or CAR-T therapy.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The vaccine may not produce a strong immune response in these patients due to their weakened immune systems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.